CHMP gives positive opinion on pretomanid (Pretomanid FGK)

The CHMP have recommended market authorisation of pretomanid, in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis.

European Medicines Agency